Canget BioTekpharma, a Buffalo-based startup supported by UB Business and Entrepreneur Partnerships, received FDA Rare Pediatric Disease and Orphan Drug designations for FL118, a potential treatment for osteosarcoma, advancing efforts to develop new therapies for this rare and aggressive bone cancer affecting children and young adults.






















